Have a feature idea you'd love to see implemented?
Let us know!
AUTL Autolus Therapeutics plc
Price (delayed)
$2.84
Market cap
$755.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
$398.42M
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a
Highlights
Autolus Therapeutics's equity has surged by 164% YoY but it has decreased by 10% QoQ
Autolus Therapeutics's quick ratio has surged by 83% YoY but it has decreased by 27% QoQ
Autolus Therapeutics's net income has shrunk by 71% YoY and by 15% QoQ
AUTL's debt has soared by 56% year-on-year and by 4.3% since the previous quarter
Key stats
What are the main financial stats of AUTL
Market
Valuations
Earnings
Shares outstanding
266.12M
Market cap
$755.79M
Enterprise value
$398.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
74.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.48
Revenue
$10.09M
EBIT
-$187.54M
EBITDA
-$172.59M
Free cash flow
-$205.61M
Per share
Balance sheet
Liquidity
EPS
-$1.22
Free cash flow per share
-$0.77
Book value per share
$1.79
Revenue per share
$0.04
TBVPS
$3.11
Total assets
$827.49M
Total liabilities
$350.53M
Debt
$301.17M
Equity
$476.97M
Working capital
$665.64M
Debt to equity
0.63
Current ratio
13.69
Quick ratio
12.55
Net debt/EBITDA
2.07
Margins
Efficiency
Dividend
EBITDA margin
-1,710.4%
Gross margin
100%
Net margin
-2,677.9%
Operating margin
-2,045.9%
Return on assets
-36.5%
Return on equity
-63.6%
Return on invested capital
-49.9%
Return on capital employed
-24.2%
Return on sales
-1,858.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AUTL stock price
How has the Autolus Therapeutics stock price performed over time
Intraday
1.43%
1 week
-5.65%
1 month
-37.17%
1 year
-29.88%
YTD
-55.9%
QTD
-21.76%
Financial performance
How have Autolus Therapeutics's revenue and profit performed over time
Revenue
$10.09M
Gross profit
$10.09M
Operating income
-$206.45M
Net income
-$270.23M
Gross margin
100%
Net margin
-2,677.9%
The company's gross profit has surged by 83% YoY but it fell by 3.9% QoQ
Autolus Therapeutics's revenue has soared by 83% YoY but it has decreased by 3.9% from the previous quarter
Autolus Therapeutics's net income has shrunk by 71% YoY and by 15% QoQ
Autolus Therapeutics's operating income has decreased by 50% YoY and by 14% QoQ
Growth
What is Autolus Therapeutics's growth rate over time
Valuation
What is Autolus Therapeutics stock price valuation
P/E
N/A
P/B
1.58
P/S
74.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.48
The EPS has declined by 24% year-on-year and by 4.3% since the previous quarter
Autolus Therapeutics's equity has surged by 164% YoY but it has decreased by 10% QoQ
AUTL's price to book (P/B) is 62% lower than its last 4 quarters average of 4.2 and 28% lower than its 5-year quarterly average of 2.2
Autolus Therapeutics's revenue has soared by 83% YoY but it has decreased by 3.9% from the previous quarter
AUTL's price to sales (P/S) is 69% lower than its last 4 quarters average of 244.7 and 65% lower than its 5-year quarterly average of 216.5
Efficiency
How efficient is Autolus Therapeutics business performance
The return on sales has declined by 24% since the previous quarter but it has grown by 15% year-on-year
Autolus Therapeutics's ROIC has decreased by 11% from the previous quarter and by 8% YoY
The return on equity has grown by 4.8% since the previous quarter and by 2% year-on-year
Autolus Therapeutics's return on assets has decreased by 4.3% YoY
Dividends
What is AUTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AUTL.
Financial health
How did Autolus Therapeutics financials performed over time
The company's total assets is 136% higher than its total liabilities
The company's total assets has surged by 104% YoY but it fell by 3.1% QoQ
Autolus Therapeutics's quick ratio has surged by 83% YoY but it has decreased by 27% QoQ
AUTL's debt is 37% smaller than its equity
Autolus Therapeutics's equity has surged by 164% YoY but it has decreased by 10% QoQ
AUTL's debt has soared by 56% year-on-year and by 4.3% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.